Treatment of endocrine-resistent stage D carcinoma of prostate with a cisplatin derivative (DWA2114R): A pilot study

Y. Arai, T. Matsuda, T. Kamoto, T. Hashimura, K. Oishi, H. Takeuchi, O. Yoshida

研究成果: Article査読

抄録

DWA2114R (DWA) is a new derivative of platin compounds. Eleven patients with rapidly progressive, endocrine-resistent stage D carcinoma of the prostate were treated with infusion of DWA (800 ~ 1,000 mg/m2) every 3 to 4 weeks. A partial objective response was observed in 3 of 11 patients (27%). This response lasted from 5 to 11 months with an average of 7.7 months. Six patients (55%) had a significant decrease or disappearance of bone pain and five became ambulatory and asymptomatic. Four patients (36%) showed no change, and four patients (36%) did not respond to the treatment and showed progression of their disease. There were no patients with severe leukopenia (< 1,000/mm3). No significant renal toxicity was observed in any of the patients and gastrointestinal toxicity was tolerable. DWA appears to be an effective drug available for the treatment of endocrine-resistent advanced carcinoma of the prostate.

本文言語English
ページ(範囲)897-902
ページ数6
ジャーナルActa Urologica Japonica
38
8
出版ステータスPublished - 1992 1 1

ASJC Scopus subject areas

  • 泌尿器学

フィンガープリント

「Treatment of endocrine-resistent stage D carcinoma of prostate with a cisplatin derivative (DWA2114R): A pilot study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル